Histone deacetylase (HDAC) inhibitor (HDACi) is a potent antitumor drug candidate for synovial sarcoma (SS) treatment.
Histone deacetylase (HDAC) inhibitor (HDACi) is a potent antitumor drug candidate for synovial sarcoma (SS) treatment. Twist1 expression often causes drug resistance. SN38 overcomes Twist1-induced drug resistance for HDACi through the suppression of Twist1 protein expression in SS cells.